-
MDA 2026: ‘Body of evidence for Elevidys continues to grow’
Boys with Duchenne muscular dystrophy (DMD) who received Sarepta Therapeutics’ gene therapy Elevidys (delandistrogene moxeparvovec-rokl)
-
Sarepta Announces Plans to Submit sNDAs for AMONDYS 45 and VYONDYS 53
Today, Sarepta Therapeutics announced plans to submit supplemental New Drug Applications (sNDAs) to the U.S.








